: Recurrence-free survival with 1L DT or IO as adjuvant therapy for BRAF + melanoma
Search Results
Sanjay Chandrasekaran, You-Li Ling, Jackson Tang, Deborah Norton, and Rohan Shah
William C. Huang and Bernard H. Bochner
Since the advent of effective chemotherapeutic regimens for treating transitional cell carcinoma, multimodal therapy has become part of the contemporary management of patients with muscle-invasive bladder cancer. However, radical cystectomy with pelvic lymphadenectomy remains the cornerstone of treatment for patients with localized and regionally advanced muscle-invasive disease. The effectiveness of chemotherapy models in bladder cancer can depend greatly on the quality of surgery. Unfortunately, without sufficient level I data, the boundaries of lymphadenectomy and the diagnostic and therapeutic ramifications of variations in the pelvic lymph node dissection remain undetermined. This article examines the role of pelvic lymph node dissection during perioperative chemotherapy and discusses the current challenges in establishing standards for lymphadenectomy in patients undergoing treatment for muscle-invasive bladder cancer.
Daniel G. Coit
guidelines for physicians treating patients with melanoma of all stages. We were to develop recommendations for the diagnosis, workup, initial treatment including adjuvant therapy, follow-up, and management of recurrent disease. Over the ensuing 2 decades
Laura M. Spring, Yael Bar, and Steven J. Isakoff
evolving neoadjuvant therapy trial designs. (A) Traditional neoadjuvant trials randomize all therapy preoperatively, followed by standard subtype-specific adjuvant therapy regardless of pathologic response. (B) Postneoadjuvant/residual disease trials
Presenter: Genevieve Boland
adjuvant therapy trials of immune checkpoint inhibitors (ICIs) in stage III–IV melanoma and their outcomes. Figure 1. Adjuvant therapy in stage III–IV melanoma. Abbreviations: D/T, dabrafenib + trametinib; DMFS, distant metastasis–free survival; HR
Jordan McDonald, Anupam Rishi, Sabrina Saeed, Rutika Mehta, David Pointer, Jessica Frakes, Sarah Hoffe, Jacques Fontaine, and Jose Pimiento
Julie Hallet, Bourke Tillman, Jesse Zuckerman, Matthew P. Guttman, Tyler Chesney, Alyson L. Mahar, Wing C. Chan, Natalie Coburn, Barbara Haas, and members of the Recovery after Surgical Therapy for Older adults Research–Cancer (RESTORE-Cancer) Group
). Adjusted for age (categorical), sex, rural residence, comorbidity burden, material deprivation, immigration status, stage at diagnosis, year of surgery, neoadjuvant therapy, adjuvant therapy, intensity of surgical procedure, and cancer type. Subgroup
Daniel G. Coit, John A. Thompson, Alain Algazi, Robert Andtbacka, Christopher K. Bichakjian, William E. Carson III, Gregory A. Daniels, Dominick DiMaio, Marc Ernstoff, Ryan C. Fields, Martin D. Fleming, Rene Gonzalez, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr, Richard W. Joseph, Julie R. Lange, Mary C. Martini, Miguel A. Materin, Anthony J. Olszanski, Merrick I. Ross, April K. Salama, Joseph Skitzki, Jeff Sosman, Susan M. Swetter, Kenneth K. Tanabe, Javier F. Torres-Roca, Vijay Trisal, Marshall M. Urist, Nicole McMillian, and Anita Engh
statistically significant improvement in relapse-free survival ( Table 1 ). Intermediate-dose IFN, defined as 5 to 10 MU per day subcutaneously for 3 to 5 days per week, has also been compared with observation as adjuvant therapy for resected, high-risk melanoma
Anthony J. Olszanski
Patients with stage III melanoma are at high risk for disease recurrence, but adjuvant therapy—including targeted therapy and immunotherapy—may prevent or delay relapse, according to Anthony J. Olszanski, MD, RPh, Associate Professor and Vice Chair
Charles L. Loprinzi and Peter M. Ravdin
. 5 Ravdin PM Siminoff LA Davis GJ . Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer . J Clin Oncol 2001 ; 19 : 980 - 991 . 6 Loprinzi CL Thome SD . Understanding the utility
